Inpharma 1310 - 20 Oct 2001

■ S 239061* shows ‘impressive’ antitumour activityafter IV or oral administration in tumour-bearing mice,report researchers from France. In this study, groupsof such mice were administered IV or oral S 239061,acronycine, fluorouracil, irinotecan [‘Campto’],vinorelbine [‘Navelbine’], paclitaxel, or no treatment(controls). In colon tumour-bearing mice, IVadministration of S 239061 1.56–6.25 mg/kg markedlyinhibited tumour growth, showed 16-fold greaterpotency compared with acronycine and was superiorto fluorouracil. Similarly, IV or oral administration of S239061 in human orthotopic tumour models showeda marked antitumour activity against humancarcinomas and was significantly more effective thanvinorelbine or irinotecan.* Servier; preclinical for cancer

Guilbaud N, et al. Marked antitumor activity of a new potent acronycinederivative in orthotopic models of human solid tumors. Clinical cancerresearch: an official journal of the American Association for Cancer Research7: 2573-2580, Aug 2001 800881230

1

Inpharma 20 Oct 2001 No. 13101173-8324/10/1310-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved